Literature DB >> 23670841

[Ocular myasthenia gravis].

S Pitz1, B Jordan, S Zierz.   

Abstract

Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to provide a pragmatic approach to the pathogenesis, clinical features, diagnostics and therapeutic strategies in the clinical routine.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23670841     DOI： 10.1007/s00347-013-2833-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  16 in total

1.  Edrophonium infrared optokinetic nystagmography in the diagnosis of myasthenia gravis.

Authors:  R H Spector; R B Daroff
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis.

Authors:  Maria Elena Farrugia; Robin P Kennett; John Newsom-Davis; David Hilton-Jones; Angela Vincent
Journal:  Muscle Nerve       Date:  2006-04       Impact factor: 3.217

Review 3.  Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy.

Authors:  Molly E Gilbert; Eduardo A De Sousa; Peter J Savino
Journal:  Arch Neurol       Date:  2007-12

Review 4.  Medical and surgical treatment for ocular myasthenia.

Authors:  Michael Benatar; Henry Kaminski
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  Thymectomy in the treatment of ocular myasthenia gravis.

Authors:  P F Roberts; F Venuta; E Rendina; T De Giacomo; G F Coloni; D M Follette; D P Richman; J R Benfield
Journal:  J Thorac Cardiovasc Surg       Date:  2001-09       Impact factor: 5.209

6.  Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Authors:  G O Skeie; S Apostolski; A Evoli; N E Gilhus; I Illa; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal:  Eur J Neurol       Date:  2010-04-12       Impact factor: 6.089

Review 7.  Ocular myasthenia: a protean disorder.

Authors:  D A Weinberg; R L Lesser; T L Vollmer
Journal:  Surv Ophthalmol       Date:  1994 Nov-Dec       Impact factor: 6.048

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Mechanisms of acetylcholine receptor loss in myasthenia gravis.

Authors:  D B Drachman; R N Adams; E F Stanley; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

Review 10.  Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  Michael Benatar; Henry J Kaminski
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910
View more
  2 in total

1.  [Sudden onset diplopia].

Authors:  D Besch; F Schuettauf
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

2.  Neuro-Ophthalmology at the Bedside: A Clinical Guide.

Authors:  Josef G Heckmann; Ivana Vachalova; Christoph J G Lang; Susanne Pitz
Journal:  J Neurosci Rural Pract       Date:  2018 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.